Compare Repligen Corporation Common Stock (RGEN) vs Trekor Metals Limited Common Shares (TGB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Trekor Metals Limited Common Shares — how do they compare? Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B), while Trekor Metals Limited Common Shares trades at $8.2 (market cap $3.12B). The key difference: Repligen Corporation Common Stock is far larger — about 3.6× Trekor Metals Limited Common Shares's market cap, and Trekor Metals Limited Common Shares is more actively traded (3,598,372 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Trekor Metals Limited Common Shares for 4 Days on average.
| RGEN | TGB | |
|---|---|---|
Market Cap | $11.14B | $3.12B |
Volume | 1,259,263 | 3,598,372 |
Sector | Health | Basic Materials |
52-Week High | $194.57 | $9.68 |
52-Week Low | $102.87 | $3.75 |
Typical Hold Time | 0 Days | 4 Days |
Enterprise Value | $11.02B | $3.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TGB trades at $8.56, down 1.72% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue projected to grow from $673M in 2025 to $985M in 2026, turning from a net loss of $30M to a $16M profit. Recent copper production announcements highlight operational strength, though valuation metrics remain elevated with a P/E of 406.88. Analyst sentiment is mixed with a 25% buy rating amid balanced hold/sell recommendations.
The outlook for TGB hinges on copper production growth from Gibraltar and Florence mines, supporting revenue expansion and margin improvement. Key risks include execution challenges in mine ramp-ups, commodity price volatility, and high debt levels. While technical indicators suggest near-term upside, the stock's rich valuation requires careful monitoring of earnings delivery against expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Trekor Metals Limited Common Shares
Trekor Metals is a mining company focused on copper. It operates the Gibraltar Mine and develops projects involving copper, gold, silver, and niobium.
Read more on TGB →
